Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
University of Ulm
Pfizer
Amgen
University of Ulm
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
University of Kansas Medical Center
New Mexico Cancer Research Alliance